Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.8%

16 terminated/withdrawn out of 95 trials

Success Rate

80.7%

-5.9% vs industry average

Late-Stage Pipeline

15%

14 trials in Phase 3/4

Results Transparency

63%

42 of 67 completed trials have results

Key Signals

6 recruiting42 with results14 terminated

Enrollment Performance

Analytics

Phase 2

37(43.0%)

Phase 1

35(40.7%)

Phase 3

13(15.1%)

Phase 4

1(1.2%)

86Total

Phase 2(37)

Phase 1(35)

Phase 3(13)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (95)

Showing 20 of 95 trials

NCT06524583Phase 2Recruiting

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Role: collaborator

NCT07839819Phase 1Not Yet Recruiting

Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies

Role: lead

NCT05153239Phase 3Completed

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Role: lead

NCT07644039Phase 1Recruiting

Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies

Role: lead

NCT06766825Phase 2Active Not Recruiting

Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)

Role: collaborator

NCT06088290Phase 3Active Not Recruiting

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

Role: lead

NCT05076396Phase 1Completed

PM14 Administered Intravenously to Patients With Advanced Solid Tumors

Role: lead

NCT04305548Phase 2Recruiting

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Role: collaborator

NCT04383119Phase 2Recruiting

Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Role: collaborator

NCT02805725Phase 1Completed

Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide

Role: collaborator

NCT06050434Terminated

Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients

Role: collaborator

NCT05841563Phase 1Recruiting

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

Role: lead

NCT05072106Phase 1Completed

Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Role: lead

NCT03085225Phase 1Completed

Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.

Role: collaborator

NCT05063318Phase 1Completed

Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Role: lead

NCT05835609Phase 1Recruiting

PM534 Administered Intravenously to Patients With Advanced Solid Tumors

Role: lead

NCT02611024Phase 1Completed

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Role: lead

NCT04358237Phase 1Completed

Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.

Role: collaborator

NCT03164980Phase 4Terminated

QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer

Role: collaborator

NCT04784559Phase 3Terminated

Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Role: lead